RESUMEN
Patients with inflammatory bowel diseases are susceptible to thrombosis in the active phase of the disease. Tests and some factors of coagulability have shown the existence of hypercoagulability of the blood in the active phase of these diseases. In the last few years some authors have found increased levels of antiphospholipid antibodies in the blood of patients with severe forms of Crohn's disease and ulcerative colitis. In a prospective study anticardiolipin antibodies have been measured in the blood of 12 patients, eight with ulcerative colitis and four with Crohn's disease. Six patients with ulcerative colitis and two with Crohn's disease were in the active phase of the disease, and the others in the remission. None of the patients had any clinical signs of thrombosis. Anticardiolipin antibodies were slightly increased in only one patient with severe ulcerative colitis complicated with erythema nodosum and swelling of the ankles. In nine patients anticardiolipin antibodies were in the normal range, but in two they were not found. Results of our study do not allow any definite conclusion regarding the possible role of antiphospholipid antibodies in the development of thrombosis in inflammatory bowel diseases: the number of the patients is relatively low and in half of the cases the disease was moderately active. Further studies are therefore necessary.
Asunto(s)
Anticuerpos Antifosfolípidos/sangre , Colitis Ulcerosa/inmunología , Enfermedad de Crohn/inmunología , Adulto , Colitis Ulcerosa/complicaciones , Enfermedad de Crohn/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Trombosis/complicacionesRESUMEN
In an open study the clinical efficacy of famotidine 40 mg on a duodenal ulcer was compared to that of proglumide 1600 mg. The study included 106 patients with acute duodenal ulcer, divided into two groups: A-famotidine and B-proglumide. There were no significant differences between the groups in baseline characteristics. Due to different reasons nine patients were excluded from analysis. Duodenal ulcer diagnosis and healing were determined exclusively by endoscopy. Ulcer healing was observed after four weeks in 40/49 (81.6%) patients in group A and 35/48 (72.9%) patients in group B and in 46/49 (94%) and 40/48 (83.3) after eight weeks, respectively. There were no statistically significant differences between the healing rates for both groups (p > 0.05). The reduction of ulcer related symptoms and antacid consumption was equal in both groups. No adverse effects were reported in the group A, but there were three patients with transient skin rush in the group B. Reported adverse effects were minor and did not merit exclusion from the study. It was concluded that the efficacy of famotidine 40 mg vs. proglumide 1600 mg was similar, although famotidine had proportionally better effect than proglumide. These findings supported the hypothesis that famotidine suppressed acid secretion stronger than proglumide.
Asunto(s)
Antiulcerosos/uso terapéutico , Úlcera Duodenal/tratamiento farmacológico , Famotidina/uso terapéutico , Proglumida/uso terapéutico , Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The etiologic relationship of hepatocellular carcinoma (HCC) and chronic hepatitis B viral infection was proved clinically, epidemiologically, virologically, serologically and by other methods. Together with viruses, carcinogenesis is promoted by faster recovery of hepatocytes (liver cirrhosis, chronic hepatitis, etc.). We have discovered 103 HCC in the period of 21 years. There were 81 men and 22 women; they were in the sixth and seventh decade of life in 90% of cases. Liver cirrhosis was also confirmed in 55% of cases and chronic hepatitis in 19%, namely, in 74% of patients HCC has developed on the changed liver. Fifty three patients were HBsAg positive (51.45%). The ultrasound and determination of alpha-feto proteins proved to be most valuable. It is a slow growing tumour and by its early detection surgical treatment is possible.